캔자스의 골수섬유증 임상 시험
골수섬유증 관련 연구 6개가 캔자스 내 여러 지역에서 참여자를 모집하고 있습니다.
공식 연구 텍스트(영어)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
피험자 모집 중초기 1상건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 17. 업데이트됨 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
피험자 모집 중2상
18세 ~ 66세 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
피험자 모집 중3상
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT06479135ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.